TY - JOUR T1 - Germline mutations in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer JF - medRxiv DO - 10.1101/2020.08.09.20171165 SP - 2020.08.09.20171165 AU - Megan Ren AU - Anali Orozco AU - Kang Shao AU - Anaseidy Albanez AU - Jeremy Ortiz AU - Boyang Cao AU - Lusheng Wang AU - Lilian Barreda AU - Christian S. Alvarez AU - Lisa Garland AU - Dongjing Wu AU - Charles Chung AU - Jiahui Wang AU - Megan Frone AU - Sergio Ralon AU - Victor Argueta AU - Roberto Orozco AU - Eduardo Gharzouzi AU - Michael Dean Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/13/2020.08.09.20171165.abstract N2 - Background Mutations in hereditary breast cancer genes play an important role in the risk for cancer, however, little is known of the type and frequency of mutations in Central American populations, including Guatemala.Methods Two separate panels of known cancer susceptibility genes were used to sequence blood DNA from 664 unselected breast cancer cases from two large hospitals in Guatemala. Variants were annotated with ClinVar and VarSome. Data from a structured questionnaire was used to compare mutation carriers of medium and high penetrance genes.Results A total of 73 out of 664 subjects (11%) had a variant classified as pathogenic in a gene with known high or medium penetrance for inherited breast cancer. The most frequently mutated genes were BRCA1 (37/664, 5.6%) followed by BRCA2 (15/664, 2.3%), PALB2 (5/664, 0.8%) and TP53 (5/664, 0.8%). Pathogenic variants were also detected in the moderate penetrance genes ATM, BARD1, CHEK2, and MSH6, and rare pathogenic variants detected in the low penetrance genes AXIN2, FH, MLH1, MSH2, MUTYH, NF1, and SDHB. The high ratio of BRCA1/BRCA2 mutations is due to the presence of two potential founder mutations, BRCA1 c.212+1G>A splice mutation (15 cases) and BRCA1 c.799delT (9 cases). Compared to all others, cases with pathogenic mutations had a significantly earlier age at diagnosis (45 vs 51 years, P<0.001), more likely to have had diagnosis before menopause, and a higher percentage had a relative with any cancer (51% vs 37%, P=0.038) or breast cancer (33% vs 15%, P<0.001). Mammography usage was less frequent in lower SES women indicating this group is less likely to be screened for breast cancer (p < 0.001).Conclusions Guatemalan women have rates of hereditary breast cancer mutations similar to other populations, and these women are more likely to have early age at diagnosis and family history. This data supports the use of genetic testing in breast cancer patients and those at high risk as part of a strategy to reduce breast cancer mortality in Guatemala.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded in part by the Intramural Program of the NIH, the National Key Research and Development Program of China (2017YFC1309103), GRF grants CityU 11206120, CityU 11210119 and NSFC 61972329. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted at the Hospital General San Juan de Dios, a large public hospital and the Instituto de Cancerologia (INCAN) an adult cancer hospital in Guatemala City. The Research Ethical Committees of each institution approved the protocol, and the study was determined exempt from institutional review board (IRB) approval by the NIH Office of Human Studies Research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDNA sequencing data will be made available to qualified researchers through dbGAP (https://www.ncbi.nlm.nih.gov/gap/). https://www.ncbi.nlm.nih.gov/gap/ ER -